Around the same time, Denali Therapeutics also reported negative results for a Phase II/III trial of its ALS therapy DNL343. Separately, Amylyx Pharmaceuticals withdrew its US Food and Drug ...

The South San Francisco biotech announced that eIF2B agonist DNL343 was unable to slow disease progression or increase survival compared to placebo at 24 weeks in the study, conducted at Sean M ...

DNL343 (small molecule eIF2B agonist) for the treatment of amyotrophic lateral sclerosis (ALS) In January 2025, Denali announced topline results that the primary endpoint was not met in Regimen G ...

Dosing is currently ongoing. DNL343, an eIF2B activator, is being evaluated in a phase II/III HEALEY study to treat amyotrophic lateral sclerosis (ALS). However, in January 2025, Denali announced ...

and UCB's complement C5 inhibitor zilucoplan – join Denali Therapeutics' DNL343 and AbbVie/Calico's fosigotifator, both eIF2B agonists, in failing to slow disease progression in the study.

Denali Therapeutics DNLI reported a first-quarter 2025 loss of 78 cents per share, wider than the Zacks Consensus Estimate of ...

Around the same time, Denali Therapeutics also reported negative results for a Phase II/III trial of its ALS therapy DNL343. Separately, Amylyx Pharmaceuticals withdrew its US Food and Drug ...

CBS News President and CEO Wendy McMahon announced Monday she was stepping down in another stunning move for the embattled company, Fox News Digital has confirmed. Her exit follows that of ...